Compare Adaptive Biotechnologies Corp (ADPT) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.05B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.66. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | PDBC | |
|---|---|---|
Market Cap | $4.05B | — |
Sector | Health | — |
52-Week High | $25.45 | $18.91 |
52-Week Low | $12.30 | $12.90 |
Enterprise Value | $4.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
PDBC, an ETF tracking diversified commodities, trades at $17.25, up 0.12% with a bearish technical signal. Recent news highlights institutional inflows, such as Geneos Wealth Management increasing its position by 150.6% in Q1 2026 (Defense World, 2026-07-19), and a Seeking Alpha downgrade to hold due to weakening commodity momentum (2026-06-11). The ETF has outperformed the S&P 500 by nearly 10 percentage points since March 2024 but faces headwinds from oil price declines and geopolitical tensions.
Outlook is mixed: commodities offer inflation hedging potential, with PDBC surging 50% amid supply disruptions (24/7 Wall Street, 2026-05-11), but risks include a potential 'super-squeeze' from Middle East conflicts (HSBC via 24/7 Wall Street, 2026-07-24) and tax-related complexities. Investors should weigh diversification benefits against volatile commodity cycles and roll costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
